Propanc Biopharma (PPCB) Q2 2026 earnings summary

Executive summary

• No revenue was generated as the company remains in the development stage, focusing on cancer treatment research and patent expansion.

• Filed four provisional patent applications, potentially doubling the IP portfolio to over 200 patents covering new cancer and fibrosis treatments, synthetic enzyme production, and novel formulations.

• Published peer-reviewed research demonstrating the efficacy of proenzymes in disrupting the tumor microenvironment in pancreatic ductal adenocarcinoma.

• Preparing for a Phase 1b, first-in-human study of lead asset PRP in advanced cancer patients, with manufacturing and analytical partnerships established.

Financial highlights

• Net loss for the quarter ended December 31, 2025, was $3.1 million, and for the six months was $8.86 million, both up significantly year-over-year.

• Administrative expenses rose to $3.6 million for the quarter and $8.2 million for the six months, primarily due to $6.2 million in stock-based consulting and advisory fees.

• Cash at period end was $561,237, compared to $12,088 at June 30, 2025.

• Total assets as of December 31, 2025: $15.11 million, down from $19.63 million at June 30, 2025.

• Convertible notes reduced to $55,000 from $538,000.

Outlook and guidance

• Management highlights substantial doubt about the company's ability to continue as a going concern due to recurring losses, negative working capital, and dependence on external financing.

• Financing facility of up to $100 million secured, with $1.5 million received to date, expected to support ongoing R&D and clinical advancement.

• Ongoing efforts to secure additional funding through equity and debt offerings are critical for future operations.